Literature DB >> 33947957

A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer.

Xi Jiao1, Xin Wei2, Shuang Li1, Chang Liu1, Huan Chen3, Jifang Gong1, Jian Li1, Xiaotian Zhang1, Xicheng Wang1, Zhi Peng1, Changsong Qi1, Zhenghang Wang1, Yujiao Wang1, Yanni Wang1, Na Zhuo1, Henghui Zhang4, Zhihao Lu5, Lin Shen6.   

Abstract

The association between genetic variations and immunotherapy benefit has been widely recognized, while such evidence in gastrointestinal cancer remains limited. We analyzed the genomic profile of 227 immunotherapeutic gastrointestinal cancer patients treated with immunotherapy, from the Memorial Sloan Kettering (MSK) Cancer Center cohort. A gastrointestinal immune prognostic signature (GIPS) was constructed using LASSO Cox regression. Based on this signature, patients were classified into two subgroups with distinctive prognoses (p < 0.001). The prognostic value of the GIPS was consistently validated in the Janjigian and Pender cohort (N = 54) and Peking University Cancer Hospital cohort (N = 92). Multivariate analysis revealed that the GIPS was an independent prognostic biomarker. Notably, the GIPS-high tumor was indicative of a T-cell-inflamed phenotype and immune activation. The findings demonstrated that GIPS was a powerful predictor of immunotherapeutic survival in gastrointestinal cancer and may serve as a potential biomarker guiding immunotherapy treatment decisions.

Entities:  

Year:  2021        PMID： 33947957     DOI： 10.1038/s41698-021-00172-5

Source DB:  PubMed          Journal:  NPJ Precis Oncol        ISSN： 2397-768X


  49 in total

1.  Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

Authors:  Michael J Overman; Ray McDermott; Joseph L Leach; Sara Lonardi; Heinz-Josef Lenz; Michael A Morse; Jayesh Desai; Andrew Hill; Michael Axelson; Rebecca A Moss; Monica V Goldberg; Z Alexander Cao; Jean-Marie Ledeine; Gregory A Maglinte; Scott Kopetz; Thierry André
Journal:  Lancet Oncol       Date:  2017-07-19       Impact factor: 41.316

2.  Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.

Authors:  Aurelien Marabelle; Dung T Le; Paolo A Ascierto; Anna Maria Di Giacomo; Ana De Jesus-Acosta; Jean-Pierre Delord; Ravit Geva; Maya Gottfried; Nicolas Penel; Aaron R Hansen; Sarina A Piha-Paul; Toshihiko Doi; Bo Gao; Hyun Cheol Chung; Jose Lopez-Martin; Yung-Jue Bang; Ronnie Shapira Frommer; Manisha Shah; Razi Ghori; Andrew K Joe; Scott K Pruitt; Luis A Diaz
Journal:  J Clin Oncol       Date:  2019-11-04       Impact factor: 44.544

3.  Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.

Authors:  Charles S Fuchs; Toshihiko Doi; Raymond W Jang; Kei Muro; Taroh Satoh; Manuela Machado; Weijing Sun; Shadia I Jalal; Manish A Shah; Jean-Phillipe Metges; Marcelo Garrido; Talia Golan; Mario Mandala; Zev A Wainberg; Daniel V Catenacci; Atsushi Ohtsu; Kohei Shitara; Ravit Geva; Jonathan Bleeker; Andrew H Ko; Geoffrey Ku; Philip Philip; Peter C Enzinger; Yung-Jue Bang; Diane Levitan; Jiangdian Wang; Minori Rosales; Rita P Dalal; Harry H Yoon
Journal:  JAMA Oncol       Date:  2018-05-10       Impact factor: 31.777

4.  Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma.

Authors:  Toshihiko Doi; Sarina A Piha-Paul; Shadia I Jalal; Sanatan Saraf; Jared Lunceford; Minori Koshiji; Jaafar Bennouna
Journal:  J Clin Oncol       Date:  2017-11-08       Impact factor: 44.544

5.  Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.

Authors:  Ken Kato; Byoung Chul Cho; Masanobu Takahashi; Morihito Okada; Chen-Yuan Lin; Keisho Chin; Shigenori Kadowaki; Myung-Ju Ahn; Yasuo Hamamoto; Yuichiro Doki; Chueh-Chuan Yen; Yutaro Kubota; Sung-Bae Kim; Chih-Hung Hsu; Eva Holtved; Ioannis Xynos; Mamoru Kodani; Yuko Kitagawa
Journal:  Lancet Oncol       Date:  2019-09-30       Impact factor: 41.316

6.  Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.

Authors:  Jing Huang; Jianming Xu; Yun Chen; Wu Zhuang; Yiping Zhang; Zhendong Chen; Jia Chen; Helong Zhang; Zuoxing Niu; Qingxia Fan; Lizhu Lin; Kangsheng Gu; Ying Liu; Yi Ba; Zhanhui Miao; Xiaodong Jiang; Ming Zeng; Jianhua Chen; Zhichao Fu; Lu Gan; Jun Wang; Xianbao Zhan; Tianshu Liu; Zhiping Li; Lin Shen; Yongqian Shu; Tao Zhang; Qing Yang; Jianjun Zou
Journal:  Lancet Oncol       Date:  2020-05-13       Impact factor: 41.316

7.  Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.

Authors:  Ronan J Kelly; Jeeyun Lee; Yung-Jue Bang; Khaldoun Almhanna; Mariela Blum-Murphy; Daniel V T Catenacci; Hyun Cheol Chung; Zev A Wainberg; Michael K Gibson; Keun-Wook Lee; Johanna C Bendell; Crystal S Denlinger; Cheng Ean Chee; Takeshi Omori; Rom Leidner; Heinz-Josef Lenz; Yee Chao; Marlon C Rebelatto; Philip Z Brohawn; Peng He; Jennifer McDevitt; Siddharth Sheth; Judson M Englert; Geoffrey Y Ku
Journal:  Clin Cancer Res       Date:  2019-11-01       Impact factor: 12.531

Review 8.  Immunotherapeutic advances in gastrointestinal malignancies.

Authors:  Devika Rao; Ruwan Parakrama; Titto Augustine; Qiang Liu; Sanjay Goel; Radhashree Maitra
Journal:  NPJ Precis Oncol       Date:  2019-02-05

9.  Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432.

Authors:  F Wang; X L Wei; F H Wang; N Xu; L Shen; G H Dai; X L Yuan; Y Chen; S J Yang; J H Shi; X C Hu; X Y Lin; Q Y Zhang; J F Feng; Y Ba; Y P Liu; W Li; Y Q Shu; Y Jiang; Q Li; J W Wang; H Wu; H Feng; S Yao; R H Xu
Journal:  Ann Oncol       Date:  2019-09-01       Impact factor: 32.976

10.  Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer.

Authors:  Saori Mishima; Akihito Kawazoe; Yoshiaki Nakamura; Akinori Sasaki; Daisuke Kotani; Yasutoshi Kuboki; Hideaki Bando; Takashi Kojima; Toshihiko Doi; Atsushi Ohtsu; Takayuki Yoshino; Takeshi Kuwata; Akihito Tsuji; Kohei Shitara
Journal:  J Immunother Cancer       Date:  2019-01-31       Impact factor: 13.751
View more
  5 in total

Review 1.  Functional Impact of Risk Gene Variants on the Autoimmune Responses in Type 1 Diabetes.

Authors:  Chelsea Gootjes; Jaap Jan Zwaginga; Bart O Roep; Tatjana Nikolic
Journal:  Front Immunol       Date:  2022-05-04       Impact factor: 8.786

2.  Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer.

Authors:  Zhihao Lu; Huan Chen; Xi Jiao; Yujiao Wang; Lijia Wu; Huaibo Sun; Shuang Li; Jifang Gong; Jian Li; Jianling Zou; Keyan Yang; Ying Hu; Beibei Mao; Lei Zhang; Xiaotian Zhang; Zhi Peng; Ming Lu; Zhenghang Wang; Henghui Zhang; Lin Shen
Journal:  Genome Med       Date:  2021-11-03       Impact factor: 11.117

3.  A Neutrophil Extracellular Traps Signature Predicts the Clinical Outcomes and Immunotherapy Response in Head and Neck Squamous Cell Carcinoma.

Authors:  Naifei Chen; Dongsheng He; Jiuwei Cui
Journal:  Front Mol Biosci       Date:  2022-02-18

4.  The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma.

Authors:  Zhihao Lu; Silu Yang; Xuerui Luo; Yang Shi; Jong-Seok Lee; Sanjeev Deva; Tianshu Liu; Yee Chao; Yun Zhang; Ruiqi Huang; Yaling Xu; Zhirong Shen; Lin Shen
Journal:  Gastric Cancer       Date:  2022-07-02       Impact factor: 7.701

5.  Pancancer analysis of a potential gene mutation model in the prediction of immunotherapy outcomes.

Authors:  Lishan Yu; Caifeng Gong
Journal:  Front Genet       Date:  2022-08-26       Impact factor: 4.772
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.